I believe this is a game changer, for those of us who aren't as brave as @Jack17 & others who have tried going back on fin.
This Progestin Based 'sarm' which acts on our progesterone receptors, possibly similar to RU or FIN, but safer in my opinion.
So what does YK-11 do?
In the 2011 paper it was speculated that YK will operate as an Anti Andorgen (stopping testosterone etc binding in the body). With some anabolic potential in low levels of Test/DHT. As a derivative of DHT it is likely that little muscle mass gains can be achieved directly from it. However, muscle retention, muscle hardness, strength and Libido are likely to increase. Meaning it would be a compound bodybuilders would run going into a show rather than during the off season, yet it is often marketed a mass builder.
As stated in the 2011 paper YK was chemically designed from ethisterone (steroidal progestin) it is of a similar structure to Norethynodrel which is likely to make it either to activate or inhibit progesterone receptors. This though is mainly based on scientific theory rather than studies due to it being unproven.
YK11 is a partial agonist of the androgen receptor with a greater effect on increasing follistatin than DHT does (Kano et all 2013 Selective Androgen Receptor Modulator, YK11, Regulates Myogenic Differentiation of C2C12 Myoblasts by Follistatin Expression). What follistatin does is it inhibits the action of myostatin. Myostatin inhibits the actions of Myf5, MyoD, and myogenin. Myf5, MyoD, and myogenin induces muscle growth. This is excellent news for us but there is a negative aspect of YK11 being a partial agnonist of the androgen receptor. YK11 may inhibit testosterone and DHT from acting on the androgen receptor since it will compete for binding at the androgen receptor with testosterone and DHT. This is something to consider if running YK11 as there is the risk that running DHT compounds and/or testosterone or other androgens may reduce their effectiveness since YK11 will be competing with and taking up some of the androgen receptors. In a low testosterone and/or low DHT state however, YK11 would be beneficial as you have less of a risk for androgen receptor saturation. With that said, even though there is a risk of YK11 being a antiandrogen and that it may be less anabolic than DHT and/or testosterone, the effects on follistatin may counter this potential drawback. This is something which should be considered when deciding to run YK11 with other androgens.
As a bare minimum, if we cycle this on and off, to retrain our receptors... we may have the same effect as going back on FIN but without the dangers that FIN brings... I will be trying this on test first, in June... and then without test, likely towards end of year. @Trump_1776 @jinstewart @ncsugrad I believe this product to be a good test for PFS.
This Progestin Based 'sarm' which acts on our progesterone receptors, possibly similar to RU or FIN, but safer in my opinion.
So what does YK-11 do?
In the 2011 paper it was speculated that YK will operate as an Anti Andorgen (stopping testosterone etc binding in the body). With some anabolic potential in low levels of Test/DHT. As a derivative of DHT it is likely that little muscle mass gains can be achieved directly from it. However, muscle retention, muscle hardness, strength and Libido are likely to increase. Meaning it would be a compound bodybuilders would run going into a show rather than during the off season, yet it is often marketed a mass builder.
As stated in the 2011 paper YK was chemically designed from ethisterone (steroidal progestin) it is of a similar structure to Norethynodrel which is likely to make it either to activate or inhibit progesterone receptors. This though is mainly based on scientific theory rather than studies due to it being unproven.
YK11 is a partial agonist of the androgen receptor with a greater effect on increasing follistatin than DHT does (Kano et all 2013 Selective Androgen Receptor Modulator, YK11, Regulates Myogenic Differentiation of C2C12 Myoblasts by Follistatin Expression). What follistatin does is it inhibits the action of myostatin. Myostatin inhibits the actions of Myf5, MyoD, and myogenin. Myf5, MyoD, and myogenin induces muscle growth. This is excellent news for us but there is a negative aspect of YK11 being a partial agnonist of the androgen receptor. YK11 may inhibit testosterone and DHT from acting on the androgen receptor since it will compete for binding at the androgen receptor with testosterone and DHT. This is something to consider if running YK11 as there is the risk that running DHT compounds and/or testosterone or other androgens may reduce their effectiveness since YK11 will be competing with and taking up some of the androgen receptors. In a low testosterone and/or low DHT state however, YK11 would be beneficial as you have less of a risk for androgen receptor saturation. With that said, even though there is a risk of YK11 being a antiandrogen and that it may be less anabolic than DHT and/or testosterone, the effects on follistatin may counter this potential drawback. This is something which should be considered when deciding to run YK11 with other androgens.
As a bare minimum, if we cycle this on and off, to retrain our receptors... we may have the same effect as going back on FIN but without the dangers that FIN brings... I will be trying this on test first, in June... and then without test, likely towards end of year. @Trump_1776 @jinstewart @ncsugrad I believe this product to be a good test for PFS.
